Companies · Healthtech

Conversio Health, LLC

SAN LUIS OBISPO · Healthtech · refined from filed group “Other Health Care

Diligence memoA one-page analyst read on Conversio Health, LLC — recommendation, valuation, rhythm, risks.
$39.0M
Total raised · real
3
Rounds
0.8×
Latest step-up
Top 13%
Sector rank · raised
Series B
Latest stage · inferred · Sat Jan 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conversio Health, LLC looks fair against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the healthtech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.96× the median modeled value of Series B Healthtech companies in 2022–2024 (98 peers) — value vs value, same stage and era.
  • Within the normal band (96% of peer median) for its niche.
At-risk
  • Last raise 2.4 yr ago; this sector typically re-raises about every 14 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Conversio Health, LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
12.8 yr record
Peak capital year was 2024 with $48.5M across 3 filings.
Market position
ahead of 88% of Healthtech peers
Capital scale is ahead of 88% of Healthtech peers; modeled value is above 84% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Needs review
Row-level filing totals differ from canonical totals, so amendment/superseded filtering should be checked.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2024: $48.5M across 3 filings.
  • Largest single filing was $20.3M on 2024-01-27.
  • Filing rows sum to $69.4M, while canonical raised total is $39.0M; likely amendments/superseded rows are mixed into the detail view.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
  • Canonical filtering should be tightened before using row-level totals for diligence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Healthtech

Conversio Health, LLC is one of 2138 Healthtech companies tracked from SAN LUIS OBISPO. By capital raised it ranks in the upper tier (ahead of 88% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2024-01-27
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2013-09-13 Raised $15M (real) Modeled valuation $335M (est)$15M$335MSeries A2013Series A · 2020-10-14 Raised $3.9M (real) Modeled valuation $79M (est)$3.9M$79MSeries A2020Seed · 2020-10-14 Raised $2.2M (real) Modeled valuation $52M (est)$2.2M$52MSeed2020Series B · 2024-01-27 Raised $20M (real) Modeled valuation $158M (est)$20M$158MSeries B2024Series B · 2024-01-27 Raised $16M (real) Modeled valuation $123M (est)$16M$123MSeries B2024Series A · 2024-01-27 Raised $12M (real) Modeled valuation $73M (est)$12M$73MSeries A2024+$3.9M+$2.2M+$20M+$16M+$12MCumulative $69M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$14.8M · 2013
Series A extension$3.9M · 2020
Bridge · Series A-stage$2.2M · 2020smaller follow-on
Series B$20.3M · 2024
Series B extension$15.8M · 2024
Bridge · Series B-stage$12.4M · 2024smaller follow-on

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 75%.

Modeled valuation trajectory
$158.1M
Base estimate est.
$47.6M
Conservative case
$307.1M
Upside case
$112.6M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the healthtech sector profile. Directional, not a quoted figure.

Series A · modeled $334.7M · 2013-09-132013Series A · modeled $79.5M · 2020-10-14Seed · modeled $52.5M · 2020-10-14Series B · modeled $158.1M · 2024-01-27Series B · modeled $123.4M · 2024-01-27Series A · modeled $73.0M · 2024-01-272024
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
64%
Survival probability
42% low · 78% high
1.38×/yr
Annual markup
1.67×/yr upside case
2.4 yr
Elapsed time used
2.4 yr actual, capped for stale marks
healthtech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
25 mo
Avg between rounds
$3.8M/yr
Capital velocity
12.8 yr
On record since
2013
First round
6
Rounds on file
How it compares to the market

Benchmarked against 2138 companies in Healthtech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 8.7× above median
This company$39.0M
Sector median$4.5M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.7× of median
This company$12.4M
Sector median$18.3M
Modeled value — vs sector median (estimate, all stages) 4.7× above median
This company$158.1M
Sector median$33.8M

Raised more than 88% of sector peers (real $). Modeled value above 84% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #52 of 98.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0MCapital raised (log)Casana Care, Inc. · Series B Raised $56.4M · modeled $608.0M (est)Mendel Health Inc. · Series B Raised $52.7M · modeled $570.9M (est)Bicycle Health Inc. · Series B Raised $61.4M · modeled $492.6M (est)Brave Health, Inc. · Series B Raised $38.6M · modeled $485.7M (est)Flume Health, Inc. · Series B Raised $35.9M · modeled $446.0M (est)Healthy America, LLC · Series B Raised $31.0M · modeled $435.9M (est)Moxe Health Corp · Series B Raised $34.8M · modeled $404.2M (est)Kintsugi Mindful Wellness, Inc. · Series B Raised $25.0M · modeled $370.4M (est)Invoq Health, Inc. · Series B Raised $41.5M · modeled $362.5M (est)Folx Health, Inc. · Series B Raised $59.3M · modeled $355.7M (est)Recuro Health, Inc. · Series B Raised $44.2M · modeled $340.0M (est)Orchard Healthcare, Inc. · Series B Raised $34.8M · modeled $338.9M (est)Conversio Health, LLC (this company) Raised $39.0M · modeled $158.1M (est)Conversio Health, LLC
CompanyStageRaised · realValue · estvs peer med.
Casana Care, Inc.Series B$56.4M$608.0M3.68×
Mendel Health Inc.Series B$52.7M$570.9M3.45×
Bicycle Health Inc.Series B$61.4M$492.6M2.98×
Brave Health, Inc.Series B$38.6M$485.7M2.94×
Flume Health, Inc.Series B$35.9M$446.0M2.70×
Healthy America, LLCSeries B$31.0M$435.9M2.64×
Moxe Health CorpSeries B$34.8M$404.2M2.45×
Kintsugi Mindful Wellness, Inc.Series B$25.0M$370.4M2.24×
Invoq Health, Inc.Series B$41.5M$362.5M2.19×
Folx Health, Inc.Series B$59.3M$355.7M2.15×
Recuro Health, Inc.Series B$44.2M$340.0M2.06×
Orchard Healthcare, Inc.Series B$34.8M$338.9M2.05×
Conversio Health, LLC this companySeries B$39.0M$158.1M0.96×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$14.8M2013-09-13$67.4M$334.7M85%
Series A$3.9M2020-10-14$17.8M$79.5M90%
Seed$2.2M2020-10-14$10.8M$52.5M90%
Series B$20.3M2024-01-27$112.6M$158.1M90%
Series B$15.8M2024-01-27$87.9M$123.4M90%
Series A$12.4M2024-01-27$56.5M$73.0M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$14.8M2013-09-13
    • First recorded raise — entered as Series A.
    • 26 investors on this round.
  2. Series A$3.9M2020-10-14
    • Raised again after 85 mo — slower than the ~14 mo sector norm.
    • Round 3.8× smaller than the prior — bridge or down round.
    • 14 investors on this round.
  3. Seed$2.2M2020-10-14
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.8× smaller than the prior — bridge or down round.
    • 3 investors on this round.
  4. Series B$20.3M2024-01-27
    • Raised again after 39 mo — slower than the ~14 mo sector norm.
    • Round 9.4× larger than the prior — scaling up.
    • 1 investor on this round.
  5. Series B$15.8M2024-01-27
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
  6. Series A$12.4M2024-01-27
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
Intelligence
2026 ~Q1
Modeled next raise · ~25mo cadence
$12.4M
Modeled next size est.range $12.4M$19.9M
0.8×
Last step-up
$3.8M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Jonathan Phillips13 other2013-09
Rachel Kern6 other2020-10
JON PHILLIPS4 other2020-10
Rock Morphis4 other2013-09
Christopher Dooley3 other2024-01
Jesse Bland2 other2020-10
Patrick Cline2 other2013-09
James Hoxter1 other2013-09
Kirk Clove1 other2013-09
Pat Cline1 other2020-10
Richard Frank1 other2024-01
Amanda Bringe2024-01
Bartho Van Otterdyk2020-10
Christopher Wooley2024-01
Devraj Mukherjee2024-01
Dylan Herr2024-01
Matt Etheridge2020-10
Matthew Etheridge2013-09
Michael Holohan2013-09
Scott Waddell2020-10
Taylor Cline2020-10
Registry & provenance

Conversio Health, LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1587469
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Isommune, LLCBiotechnologyPre-Seed$275K$15.2Mnetwork4 shared operators
Sift Medical Data, Inc.HealthtechSeries B$30.7M$143.6Mnetwork1 shared operator · same sector · same stage
Aviacode Inc.OtherSeries B$33.8M$354.4Mnetwork2 shared operators · same stage
Cordata Healthcare Innovations, Inc.HealthtechSeries A$10.5M$14.6Mnetwork2 shared operators · same sector
Wellvana Health, LLCHealthtechSeries C$161.2M$154.4Mnetwork2 shared operators · same sector
Vivify Health, Inc.Other TechnologySeries A$16.4M$277.4Mnetwork3 shared operators
Spiro Medical Inc.HealthtechSeries B$39.1M$156.6Msame sector · same stage
Berry Street Health, Inc.HealthtechSeries B$39.2M$170.0Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Conversa Health, Inc.HealthtechSeries A$179.4M91%
Convalo Health International, Corp.HealthtechSeries A$7.8M87%
HealthVerity, Inc.HealthtechSeries D+$2.1B86%
Contego Medical IncHealthtechSeries B$235.0M86%
Contessa Health, Inc.HealthtechSeries A$158.0M86%
Connexion Health LLCHealthtechSeed$62.4M85%
Orbio Health Inc.HealthtechPre-Seed$704K85%
Healthnet, IncHealthtechPre-Seed$3.7M84%
Frequently asked
How much funding has Conversio Health, LLC raised?
Conversio Health, LLC has raised approximately $39.0M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Conversio Health, LLC's estimated valuation?
Provath's modeled valuation for Conversio Health, LLC is approximately $158.1M (modeled range $47.6M–$307.1M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Conversio Health, LLC at?
Conversio Health, LLC's latest modeled financing stage is Series B. Its most recent recorded round closed around Sat Jan 27.
What does Conversio Health, LLC do and where is it based?
Conversio Health, LLC operates in the Healthtech sector, based in SAN LUIS OBISPO.
Explore related

See where Conversio Health, LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Conversio Health, LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.